Project description
Better treatment options for a rare non-Hodgkin lymphoma
Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin lymphoma that affects any age group, with higher incidence in children and young adults. It can manifest as a systemic or localised disease with symptoms such as swollen lymph nodes, fever, fatigue, and weight loss. Treatment options include chemotherapy, radiation therapy, and stem cell transplant. The FANTOM project, supported by the Marie Skłodowska-Curie Actions programme, aims to train researchers in ALCL by using innovative model systems and multi-omics technologies. It will study the roles of the immune system and tumour stroma, developing non-invasive biomarkers and novel therapeutic approaches. This project will aid in advancing our understanding of ALCL and provide better treatment options for those affected.
Objective
The FANTOM Doctoral Network (DN) composed of 7 beneficiaries and 12 associated partners in 5 EU countries, recruiting 10 researchers and will be embedded into an established international research programme: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA) as well as a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). FANTOM will cosset and nurture the recruited researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives welcomed into these established networks. This will be achieved through a training programme conducted through research and complemented by a balanced programme of transferable skills designed with key input from both academic and industrial collaborators. The training of each fellow will be guided by an individual career development plan and supervised by a PhD committee with clearly allocated academic and industrial supervisors. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into the aforementioned networks. The research programme will address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression. Applying innovative model systems and multi-omics technologies, some performed to a single cell level, the biology of ALCL including the roles of the immune system and tumour stroma will be uncovered. These data will be applied to the development of (non-invasive) biomarkers and novel therapeutic approaches that will culminate in the design of clinical trials to address the issues of chemotherapy toxicity, over-treatment and drug resistance. The research and training activities will incorporate not only academic labs but also key research institutes, biotechnology companies, clinical trial bodies and Pharma to realise our research goals.
Fields of science
Not validated
Not validated
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
601 77 Brno
Czechia
See on map
Participants (7)
1090 Wien
See on map
10124 Torino
See on map
20126 Milano
See on map
20251 Hamburg
See on map
35122 Padova
See on map
Participation ended
79106 Freiburg
See on map
81675 Muenchen
See on map
Partners (14)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1030 Wien
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
20091 Bresso
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1030 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1030 Wien
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Participation ended
10115 Berlin
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
CB22 7SA Cambridge
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
SE1 7LY London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
81377 Munchen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Participation ended
79098 Freiburg
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
8010 Graz
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
51429 Bergisch Gladbach
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
CB2 1TN Cambridge
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2514 AA Den Haag
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
30625 Hannover
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.